The effect of targeted magnetic nanopaticles on hepatoma and the expression of bcl-2/bax protein

Abstract

The effect of targeted magnetic nanoparticles on hepatoma and the underlying mechanism were examined. Nude mice transplanted with a human hepatoma cell line (HepG2 cells) were randomized into 5 groups, including: (1) group A, receiving normal saline, (2) group B, receiving 5-fluorouracil (5-Fu), (3) group C, receiving magnetic nanoparticles containing 5-Fu, (4) group D, consisting of treatment with magnetic nanoparticles containing 5-Fu and inside magnetic field and (5) group E, receiving pure magnetic nanoparticles and inside magnetic field. Morphological features of transplanted tumors in mice in each group were observed under transmission electron microscope (TEM). The expression of bcl-2/bax protein was immunohistochemically detected by SABC method. The results showed that a large number of apoptotic tumor cells were found in group B and group D under TEM. The expression of bcl-2 protein was significantly decreased and the expression of bax protein increased significantly in both group B and D as compared with those in group A, C and E (P<0.01 for all). The decrease in bcl-2 and the increase in bax were more in group D as compared with group B (P<0.01). It is concluded that the targeted magnetic nanoparticles containing 5-Fu can improve the chemotherapeutic effect of 5-Fu by decreasing bcl-2 expression, increasing bax expression and inducing apoptosis of the liver cancer cells.

Keywords

liver neoplasms / cell line / bcl-2 / bax / magnetic nanoparticles, 5-Fu

References

[1] GongL. S., ZhangY. D., LiuS.. Target distribution of magnetic albumin nanoparticles containing adriamycin in model of transplanted liver cancer in rats. Chin J Hepatobiliary Surg (Chinese), 2003, 9(9): 543-546

[2] ParkinD. M., PisaniP., FerlayJ.. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer, 1999, 80: 827-841

[3] TangZ. Y., SunF. X., TianJ., et al.. Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World J Gastroenterol, 2001, 7: 597-601

[4] ZhouX. D., TangZ. Y., YuY. Q., et al.. Recurrence after resection of fetoprotein-positive hepatocellular carcinoma. J Cancer Res Clin Oncol, 1994, 120: 369-373

[5] ShutoT., KinoshitaH., HirohashiK., et al.. Indications for and effectiveness of a second hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology, 1996, 43: 932-937

[6] BlumH. E.. Molecular targets for prevention of hepatocellular carcinoma. Dig Dis, 2002, 20: 81-90

[7] KogureT., UenoY., IwasakiT., et al.. The efficacy of the combination therapy of 5-fluorouracil cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol, 2004, 53(4): 296-304

[8] TainokH., TsuijiA., MoritaS., et al.. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res, 2003, 23(2C): 1891-1897

[9] PohlJ., ZunaI., StremmelW., et al.. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy, 2001, 47(5): 359-65

[10] MurataK., ShirakiK., KawakitaT., et al.. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res, 2003, 23(2C): 1719-1722

[11] DizonD. S., KemenyN. E.. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol, 2002, 29(2): 126-135

[12] ZhangY. D., GongL. S., PanY. F., et al.. Target distribution of magnetic nanoparticle containing drug in vivo and its therapeutical efficiency for liver cancer. China Journal of Medical Engineering, 2003, 11(6): 18-21

[13] LvD. P., LiL. J., LiuX. Q.. Nanotechnology and treatment and prevention of tumor. Chin J Prac Surg (Chinese), 2002, 22(2): 126-128

[14] ClarkJ. W., GlicksmanA. S., WaneboH. J.. Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer, 1996, 78(3Suppl): 688-693

[15] YanX., FraserM., QiuQ., et al.. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol, 2006, 102(2): 348-355

[16] GrivicichI., RegnerA., da RochaA. B., et al.. The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy, 2005, 51(2–3): 93-102

[17] KerrJ. F., WinterfordC. M., HarmonB. V.. Apoptosis its significance in cancer and cancer therapy. Cancer, 1994, 73(8): 2013-2026

[18] YangE., ZhaJ., JockelJ., et al.. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 1995, 80(2): 285-291

[19] GottschalkA. R., BoiseL. H., OltvaiZ. N., et al.. The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death Differ, 1996, 3(1): 113-118

[20] JuinP., HuntA., LittlewoodT., et al.. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol, 2002, 22(17): 6158-6169

[21] YaoH., LiP., VentersB. J., et al.. Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem, 2008, 283(29): 20060-20068

[22] KeaneM. M., EttenbergS. A., NauM. M., et al.. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res, 1999, 59(3): 734-741

[23] WangZ., SongW., AboukameelA., et al.. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer, 2008, 123(4): 958-966

[24] DuanX. X., OuJ. S., LiY., et al.. Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol, 2005, 11(30): 4740-4744